• Brendon Wichmann posted an update 2 months, 1 week ago

    9 [0.5?68]; P = 0.008) and were more likely to have BCR-ABL1 (75 vs. 25 ; P < 0.01) and t (9; 22) (72 vs. 28 ; P < 0.05) than subjects without IKZF1 deletion.Outcomes and IKZF1 deletionMedian follow-up was 22 months (range, 2?1 months). 146 (90 ) subjects achieved complete remission. 2 subjects in the IKZF1 cohort relapsing during consolidation chemotherapy and before they could be assigned to further chemotherapy-only or an allotransplant were excluded from further analyses. 5-year NRM in the 144 subjects was 14 (95 confidence interval [CI], 6?2 ), 5-year CIR was 38 (27?9 ), 5-year LFS, 48 (36?9 ) and 5-year survival, 63 (51?2 ). In subjects with IKZF1 deletion 5-year NRM was 11 (2?0 fnins.2013.00232 ) vs. 16 (4?8 ; P = 0.736, Fig. 1a) for subjects without IKZF1 deletion. In subjects with IKZF1 deletion 5-year CIR was 55 (35?6 ) vs. 25 (12?8 ;Yao et al. BMC Cancer (2016) 16:Page 4 ofTable 1 Subject- and disease-related variablesVariable N Age, y Median (range) Gender Male WBC (?0E + 9/L) Median (range) Hemoglobin (g/L) Median (range) Platelets (?0E + 9/L) Median (range) Bone marrow blasts, Median (range) BCR-ABL1 Cytogenetics Normal Abnormal t(9;22) t(X;2)(p22;p21) del(9)(p13) inv(9) 47,+X Complex Unknowna bAll subjectsIKZF1-deleted 68 (47 )IKZF1 wild type 78 (53 )P-value27 (14?0)34 (15?0)22 (14?9)0.33 (46 )39 (54 )0.10 (0.5-435)14 (2?35)9 (0.5-168)0.90 (23?57)92 (35?48)89 (23?57)0.57 (0.2?13)58 (0.2?11)52 (2?13)0.87 (28?9)86 (28?8) 39 (75 )a88 (28?9) 13 (25 )b0.300 0.47 81 43 1 1 2 1 3319 (40 ) 38 (47 ) 31 (72 ) 1 1 1 1 3 11 (61 )28 (60 ) 43 (53 ) 12 (28 ) 0 0 1 0 30 7 (39 )0.0.8 subjects with BCR-ABL1 had no t(9;22) including 5 with QVD-OPH biological activity insufficient metaphases, 2 with an abnormal karyotype but not t(9;22) and 1 with a normal 02699931.2015.1049516 karyotype 1 subject with BCR-ABL1 had a normal karyotypeP = 0.004; Fig. 1b) for subjects without IKZF1 deletion. In subjects with IKZF1 deletion 5-year LFS was 33 (16?2 ) vs. 59 (42?3 ; P = 0.012; Fig. 1c) in subjects without IKZF1 deletion. In subjects with IKZF1 deletion 5-year survival was 48 (33?2 ) vs. 75 (57?6 ; P = 0.002; Fig. 1d) in subjects without IKZF1 deletion. There were 26 deaths in IKZF1 deletion cohort, 20 from leukemia and 6 from other causes. There were 15 deaths in the no IKZF1 deletion cohort, 5 from leukemia and 10 from other causes. Prognoses were similar in subjects with a dominant negative IKZF1 isoform compared to haplotype-insufficient subjects: 4-year NRM 14 (1?7 ) vs. 8 (0?9 ; P = 0.32); 4-year CIR 50 (29?0 ) vs. 44 (23?4 ; P = 0.54); 4-year LFS 36 (18?5 ) vs. 49 (28?7 ; P = 0.20) and 4-year survival 45 (23?5 ) vs.